schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals."
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
https://grassfed.us/Shellenberger-sister-of-Trewhitt-from-Pereiras 
.
may 16, 2018
.